ROS Cancer Research Results

ROS, Reactive Oxygen Species: Click to Expand ⟱
Source: HalifaxProj (inhibit)
Type:
Reactive oxygen species (ROS) are highly reactive molecules that contain oxygen and can lead to oxidative stress in cells. They play a dual role in cancer biology, acting as both promoters and suppressors of cancer.
ROS can cause oxidative damage to DNA, leading to mutations that may contribute to cancer initiation and progression. So normally you want to inhibit ROS to prevent cell mutations.
However excessive ROS can induce apoptosis (programmed cell death) in cancer cells, potentially limiting tumor growth. Chemotherapy typically raises ROS.
-mitochondria is the main source of reactive oxygen species (ROS) (and the ETC is heavily related)

"Reactive oxygen species (ROS) are two electron reduction products of oxygen, including superoxide anion, hydrogen peroxide, hydroxyl radical, lipid peroxides, protein peroxides and peroxides formed in nucleic acids 1. They are maintained in a dynamic balance by a series of reduction-oxidation (redox) reactions in biological systems and act as signaling molecules to drive cellular regulatory pathways."
"During different stages of cancer formation, abnormal ROS levels play paradoxical roles in cell growth and death 8. A physiological concentration of ROS that maintained in equilibrium is necessary for normal cell survival. Ectopic ROS accumulation promotes cell proliferation and consequently induces malignant transformation of normal cells by initiating pathological conversion of physiological signaling networks. Excessive ROS levels lead to cell death by damaging cellular components, including proteins, lipid bilayers, and chromosomes. Therefore, both scavenging abnormally elevated ROS to prevent early neoplasia and facilitating ROS production to specifically kill cancer cells are promising anticancer therapeutic strategies, in spite of their contradictoriness and complexity."
"ROS are the collection of derivatives of molecular oxygen that occur in biology, which can be categorized into two types, free radicals and non-radical species. The non-radical species are hydrogen peroxide (H 2O 2 ), organic hydroperoxides (ROOH), singlet molecular oxygen ( 1 O 2 ), electronically excited carbonyl, ozone (O3 ), hypochlorous acid (HOCl, and hypobromous acid HOBr). Free radical species are super-oxide anion radical (O 2•−), hydroxyl radical (•OH), peroxyl radical (ROO•) and alkoxyl radical (RO•) [130]. Any imbalance of ROS can lead to adverse effects. H2 O 2 and O 2 •− are the main redox signalling agents. The cellular concentration of H2 O 2 is about 10−8 M, which is almost a thousand times more than that of O2 •−".
"Radicals are molecules with an odd number of electrons in the outer shell [393,394]. A pair of radicals can be formed by breaking a chemical bond or electron transfer between two molecules."

Recent investigations have documented that polyphenols with good antioxidant activity may exhibit pro-oxidant activity in the presence of copper ions, which can induce apoptosis in various cancer cell lines but not in normal cells. "We have shown that such cell growth inhibition by polyphenols in cancer cells is reversed by copper-specific sequestering agent neocuproine to a significant extent whereas iron and zinc chelators are relatively ineffective, thus confirming the role of endogenous copper in the cytotoxic action of polyphenols against cancer cells. Therefore, this mechanism of mobilization of endogenous copper." > Ions could be one of the important mechanisms for the cytotoxic action of plant polyphenols against cancer cells and is possibly a common mechanism for all plant polyphenols. In fact, similar results obtained with four different polyphenolic compounds in this study, namely apigenin, luteolin, EGCG, and resveratrol, strengthen this idea.
Interestingly, the normal breast epithelial MCF10A cells have earlier been shown to possess no detectable copper as opposed to breast cancer cells [24], which may explain their resistance to polyphenols apigenin- and luteolin-induced growth inhibition as observed here (Fig. 1). We have earlier proposed [25] that this preferential cytotoxicity of plant polyphenols toward cancer cells is explained by the observation made several years earlier, which showed that copper levels in cancer cells are significantly elevated in various malignancies. Thus, because of higher intracellular copper levels in cancer cells, it may be predicted that the cytotoxic concentrations of polyphenols required would be lower in these cells as compared to normal cells."

Majority of ROS are produced as a by-product of oxidative phosphorylation, high levels of ROS are detected in almost all cancers.
-It is well established that during ER stress, cytosolic calcium released from the ER is taken up by the mitochondrion to stimulate ROS overgeneration and the release of cytochrome c, both of which lead to apoptosis.

Note: Products that may raise ROS can be found using this database, by:
Filtering on the target of ROS, and selecting the Effect Direction of ↑

Targets to raise ROS (to kill cancer cells):
• NADPH oxidases (NOX): NOX enzymes are involved in the production of ROS.
    -Targeting NOX enzymes can increase ROS levels and induce cancer cell death.
    -eNOX2 inhibition leads to a high NADH/NAD⁺ ratio which can lead to increased ROS
• Mitochondrial complex I: Inhibiting can increase ROS production
• P53: Activating p53 can increase ROS levels(by inducing the expression of pro-oxidant genes)
Nrf2 inhibition: regulates the expression of antioxidant genes. Inhibiting Nrf2 can increase ROS levels
• Glutathione (GSH): an antioxidant. Depleting GSH can increase ROS levels
• Catalase: Catalase converts H2O2 into H2O+O. Inhibiting catalase can increase ROS levels
• SOD1: converts superoxide into hydrogen peroxide. Inhibiting SOD1 can increase ROS levels
• PI3K/AKT pathway: regulates cell survival and metabolism. Inhibiting can increase ROS levels
HIF-1α inhibition: regulates genes involved in metabolism and angiogenesis. Inhibiting HIF-1α can increase ROS
• Glycolysis: Inhibiting glycolysis can increase ROS levels • Fatty acid oxidation: Cancer cells often rely on fatty acid oxidation for energy production.
-Inhibiting fatty acid oxidation can increase ROS levels
• ER stress: Endoplasmic reticulum (ER) stress can increase ROS levels
• Autophagy: process by which cells recycle damaged organelles and proteins.
-Inhibiting autophagy can increase ROS levels and induce cancer cell death.
• KEAP1/Nrf2 pathway: regulates the expression of antioxidant genes.
    -Inhibiting KEAP1 or activating Nrf2 can increase ROS levels and induce cancer cell death.
• DJ-1: regulates the expression of antioxidant genes. Inhibiting DJ-1 can increase ROS levels
• PARK2: regulates the expression of antioxidant genes. Inhibiting PARK2 can increase ROS levels
SIRT1 inhibition:regulates the expression of antioxidant genes. Inhibiting SIRT1 can increase ROS levels
AMPK activation: regulates energy metabolism and can increase ROS levels when activated.
mTOR inhibition: regulates cell growth and metabolism. Inhibiting mTOR can increase ROS levels
HSP90 inhibition: regulates protein folding and can increase ROS levels when inhibited.
• Proteasome: degrades damaged proteins. Inhibiting the proteasome can increase ROS levels
Lipid peroxidation: a process by which lipids are oxidized, leading to the production of ROS.
    -Increasing lipid peroxidation can increase ROS levels
• Ferroptosis: form of cell death that is regulated by iron and lipid peroxidation.
    -Increasing ferroptosis can increase ROS levels
• Mitochondrial permeability transition pore (mPTP): regulates mitochondrial permeability.
    -Opening the mPTP can increase ROS levels
• BCL-2 family proteins: regulate apoptosis and can increase ROS levels when inhibited.
• Caspase-independent cell death: a form of cell death that is regulated by ROS.
    -Increasing caspase-independent cell death can increase ROS levels
• DNA damage response: regulates the repair of DNA damage. Increasing DNA damage can increase ROS
• Epigenetic regulation: process by which gene expression is regulated.
    -Increasing epigenetic regulation can increase ROS levels

-PKM2, but not PKM1, can be inhibited by direct oxidation of cysteine 358 as an adaptive response to increased intracellular reactive oxygen species (ROS)

ProOxidant Strategy:(inhibit the Mevalonate Pathway (likely will also inhibit GPx)
-HydroxyCitrate (HCA) found as supplement online and typically used in a dose of about 1.5g/day or more
-Atorvastatin typically 40-80mg/day, -Dipyridamole typically 200mg 2x/day Combined effect research
-Lycopene typically 100mg/day range (note debatable as it mainly lowers NRF2)

Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy
ROS-Inducing Interventions in Cancer — Canonical + Mechanistic Reference
-generated from AI and Cancer database
ROS rating:  +++ strong | ++ moderate | + weak | ± mixed | 0 none
NRF2:        ↓ suppressed | ↑ activated | ± mixed | 0 none
Conditions:  [D] dose  [Fe] metal  [M] metabolic  [O₂] oxygen
             [L] light [F] formulation [T] tumor-type [C] combination

Item ROS NRF2 Condition Mechanism Class Remarks
ROS">Piperlongumine +++ [D][T] ROS-dominant
ROS">Shikonin +++↓/±[D][T]ROS-dominant
ROS">Vitamin K3 (menadione) +++[D]ROS-dominant
ROS">Copper (ionic / nano) +++[Fe][F]ROS-dominant
ROS">Sodium Selenite +++[D]ROS-dominant
ROS">Juglone +++[D]ROS-dominant
ROS">Auranofin +++[D]ROS-dominant
ROS">Photodynamic Therapy (PDT) +++0[L][O₂]ROS-dominant
ROS">Radiotherapy / Radiation +++0[O₂]ROS-dominant
ROS">Doxorubicin +++[D]ROS-dominant
ROS">Cisplatin ++[D][T]ROS-dominant
ROS">Salinomycin ++[D][T]ROS-dominant
ROS">Artemisinin / DHA ++[Fe][T]ROS-dominant
ROS">Sulfasalazine ++[C][T]ROS-dominant
ROS">FMD / fasting ++[M][C][O₂]ROS-dominant
ROS">Vitamin C (pharmacologic) ++[Fe][D]ROS-dominant
ROS">Silver nanoparticles ++±[F][D]ROS-dominant
ROS">Gambogic acid ++[D][T]ROS-dominant
ROS">Parthenolide ++[D][T]ROS-dominant
ROS">Plumbagin ++[D]ROS-dominant
ROS">Allicin ++[D]ROS-dominant
ROS">Ashwagandha (Withaferin A) ++[D][T]ROS-dominant
ROS">Berberine ++[D][M]ROS-dominant
ROS">PEITC ++[D][C]ROS-dominant
ROS">Methionine restriction +[M][C][T]ROS-secondary
ROS">DCA +±[M][T]ROS-secondary
ROS">Capsaicin +±[D][T]ROS-secondary
ROS">Galloflavin +0[D]ROS-secondary
ROS">Piperine +±[D][F]ROS-secondary
ROS">Propyl gallate +[D]ROS-secondary
ROS">Scoulerine +?[D][T]ROS-secondary
ROS">Thymoquinone ±±[D][T]Dual redox
ROS">Emodin ±±[D][T]Dual redox
ROS">Alpha-lipoic acid (ALA) ±[D][M]NRF2-dominant
ROS">Curcumin ±↑/↓[D][F]NRF2-dominant
ROS">EGCG ±↑/↓[D][O₂]NRF2-dominant
ROS">Quercetin ±↑/↓[D][Fe]NRF2-dominant
ROS">Resveratrol ±[D][M]NRF2-dominant
ROS">Sulforaphane ±↑↑[D]NRF2-dominant
ROS">Lycopene 0Antioxidant
ROS">Rosmarinic acid 0Antioxidant
ROS">Citrate 00Neutral


NA, Not Available: Click to Expand ⟱
none (reserved)

Scientific Papers found: Click to Expand⟱
1337- 2DG,  Rad,    2-deoxy-D-glucose causes cytotoxicity, oxidative stress, and radiosensitization in pancreatic cancer
- in-vivo, NA, NA
ChemoSen↑, GlucoseCon↓, ROS↑,
1341- 3BP,    The HK2 Dependent “Warburg Effect” and Mitochondrial Oxidative Phosphorylation in Cancer: Targets for Effective Therapy with 3-Bromopyruvate
- Review, NA, NA
Glycolysis↓, OXPHOS↓, *toxicity↓, ROS↑, GSH↓, eff↑,
5263- 3BP,  CET,    3-Bromopyruvate overcomes cetuximab resistance in human colorectal cancer cells by inducing autophagy-dependent ferroptosis
- in-vitro, CRC, DLD1 - NA, NA, HCT116
eff↑, Ferroptosis↓, TumAuto↑, Apoptosis↑, FOXO3↑, AMPKα↑, p‑Beclin-1↑, HK2↓, ATP↓, ROS↑, Dose↝, TumVol↓, TumW↓, xCT↑, GSH↓, eff↓, MDA↑,
4362- AgNPs,    Enhancing Colorectal Cancer Radiation Therapy Efficacy using Silver Nanoprisms Decorated with Graphene as Radiosensitizers
- in-vitro, CRC, HCT116 - in-vitro, CRC, HT29 - in-vivo, NA, NA
eff↑, TumCG↓, OS↑, RadioS↑, eff↑, ROS↑, DNAdam↑, eff↝,
4432- AgNPs,    Emerging nanostructure-based strategies for breast cancer therapy: innovations, challenges, and future directions
- Review, NA, NA
ROS↑, TumCP↓, Apoptosis↑,
4557- AgNPs,    The apoptotic effect of nanosilver is mediated by a ROS- and JNK-dependent mechanism involving the mitochondrial pathway in NIH3T3 cells
- in-vitro, NA, NIH-3T3 - in-vitro, CRC, HCT116
Cyt‑c↑, ROS↑, JNK↑,
4583- AgNPs,    Metal-Based Nanoparticles for Cardiovascular Diseases
- Review, NA, NA
RadioS↑, *ROS↑, *BBB↝,
342- AgNPs,    Silver nanoparticles; a new hope in cancer therapy?
- Review, NA, NA
ROS↑, DNAdam↑, Apoptosis↑, mtDam↑,
335- AgNPs,  PDT,    Biogenic Silver Nanoparticles for Targeted Cancer Therapy and Enhancing Photodynamic Therapy
- Review, NA, NA
ROS↑, GSH↓, GPx↑, Catalase↓, SOD↓, p38↑, BAX↑, Bcl-2↓,
375- AgNPs,  ALA,    Alpha-Lipoic Acid Prevents Side Effects of Therapeutic Nanosilver without Compromising Cytotoxicity in Experimental Pancreatic Cancer
- in-vitro, PC, Bxpc-3 - in-vitro, PC, PANC1 - in-vitro, PC, MIA PaCa-2 - in-vivo, NA, NA
mtDam↑, ROS↑, *toxicity↓, Dose∅, selectivity↑,
320- AgNPs,    Silver nanoparticles induce endoplasmatic reticulum stress response in zebrafish
- vitro+vivo, NA, HUH7
ROS↑, ER Stress↑, TNF-α↑,
309- AgNPs,    Interference of silver, gold, and iron oxide nanoparticles on epidermal growth factor signal transduction in epithelial cells
- in-vitro, NA, A431
ROS↑, Akt↓, p‑ERK↓,
306- AgNPs,    Cancer Therapy by Silver Nanoparticles: Fiction or Reality?
- Analysis, NA, NA
EPR↝, ROS↑, IL1↑, IL8↑, ER Stress↑, MMP9↑, MMP↓, Cyt‑c↑, Apoptosis↑, Hif1a↑, BBB↑, GutMicro↝, eff↑, eff↑, RadioS↑,
374- AgNPs,    Silver nanoparticles selectively treat triple‐negative breast cancer cells without affecting non‐malignant breast epithelial cells in vitro and in vivo
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
ER Stress↑, DNAdam↑, ROS↑, Apoptosis↑, GSH/GSSG↓, NADPH/NADP+↓, TumCG↓, UPR↑,
367- AgNPs,    Presence of an Immune System Increases Anti-Tumor Effect of Ag Nanoparticle Treated Mice
- in-vivo, NA, NA
ROS↑, mtDam↑, TumCG↓,
347- AgNPs,    The Role of Silver Nanoparticles in the Diagnosis and Treatment of Cancer: Are There Any Perspectives for the Future?
- Review, NA, NA
ROS↑, Apoptosis↑, ER Stress↑,
355- AgNPs,    Cytotoxicity and Genotoxicity of Biogenic Silver Nanoparticles in A549 and BEAS-2B Cell Lines
- in-vitro, Lung, A549 - in-vitro, NA, BEAS-2B
ROS↑, DNAdam↑, Apoptosis↑,
393- AgNPs,    Green synthesized plant-based silver nanoparticles: therapeutic prospective for anticancer and antiviral activity
- in-vitro, NA, HCT116
mtDam↑, ROS↑, TumCCA↑, Casp3↑, BAX↑, Bcl-2↓, P53↑,
2538- AgNPs,  SDT,  Z,    Dual-functional silver nanoparticle-enhanced ZnO nanorods for improved reactive oxygen species generation and cancer treatment
- Study, Var, NA - vitro+vivo, NA, NA
ROS↑, eff↑, eff↑, TumCP↓, toxicity↓,
236- AL,    Allicin: Chemistry and Biological Properties
- Analysis, NA, NA
GSH↓, Bacteria↓, LDL↓, ROS↑, NRF2↑, cognitive↑, memory↑, BP↓, RNS↓,
3438- ALA,    The Potent Antioxidant Alpha Lipoic Acid
- Review, NA, NA - Review, AD, NA
*antiOx↑, *cardioP↑, *cognitive↑, *AntiAge↑, *Inflam↓, *AntiCan↑, *neuroP↑, *IronCh↑, *ROS↑, *Weight↓, *Ach↑, *ROS↓, *GSH↑, *lipid-P↓, *memory↑, *NRF2↑, *ChAT↑, *GlucoseCon↑, *Acetyl-CoA↑,
278- ALA,    The Multifaceted Role of Alpha-Lipoic Acid in Cancer Prevention, Occurrence, and Treatment
- Review, NA, NA
ROS↑, NRF2↑, Inflam↓, frataxin↑, *BioAv↓, ChemoSen↑, Hif1a↓, eff↑, FAK↓, ITGB1↓, MMP2↓, MMP9↓, EMT↓, Snail↓, Vim↓, Zeb1↓, P53↑, MGMT↓, Mcl-1↓, Bcl-xL↓, Bcl-2↓, survivin↓, Casp3↑, Casp9↑, BAX↑, p‑Akt↓, GSK‐3β↓, *antiOx↑, *ROS↓, selectivity↑, angioG↓, MMPs↓, NF-kB↓, ITGB3↓, NADPH↓,
1235- ALA,  Cisplatin,    α-Lipoic acid prevents against cisplatin cytotoxicity via activation of the NRF2/HO-1 antioxidant pathway
- in-vitro, Nor, HEI-OC1 - ex-vivo, NA, NA
ROS↑, HO-1↓, *toxicity↓, chemoP↑, *ROS↓, *HO-1↑, *SOD1↑, *NRF2↑,
1348- And,    Andrographolide Inhibits ER-Positive Breast Cancer Growth and Enhances Fulvestrant Efficacy via ROS-FOXM1-ER-α Axis
- in-vitro, BC, MCF-7 - in-vitro, BC, T47D - in-vivo, NA, NA
ERα/ESR1↓, TumCG↓, ROS↑, FOXM1↓, eff↑,
1999- Api,  doxoR,    Apigenin ameliorates doxorubicin-induced renal injury via inhibition of oxidative stress and inflammation
- in-vitro, Nor, NRK52E - in-vitro, Nor, MPC5 - in-vitro, BC, 4T1 - in-vivo, NA, NA
neuroP↑, ChemoSen∅, RenoP↑, selectivity↑, chemoP↑, ROS↑, *ROS∅, *antiOx↑, *toxicity↓,
1547- Api,    Apigenin: Molecular Mechanisms and Therapeutic Potential against Cancer Spreading
- Review, NA, NA
angioG↓, EMT↓, CSCs↓, TumCCA↑, Dose∅, ROS↑, MMP↓, Catalase↓, GSH↓, PI3K↓, Akt↓, NF-kB↓, OCT4↓, Nanog↓, SIRT3↓, SIRT6↓, eff↑, eff↑, Cyt‑c↑, Bax:Bcl2↑, p‑GSK‐3β↓, FOXO3↑, p‑STAT3↓, MMP2↓, MMP9↓, COX2↓, MMPs↓, NRF2↓, HDAC↓, Telomerase↓, eff↑, eff↑, eff↑, eff↑, eff↑, XIAP↓, survivin↓, CK2↓, HSP90↓, Hif1a↓, FAK↓, EMT↓,
1564- Api,    Apigenin-induced prostate cancer cell death is initiated by reactive oxygen species and p53 activation
- in-vitro, Pca, 22Rv1 - in-vivo, NA, NA
MDM2↓, NF-kB↓, p65↓, P21↑, ROS↑, GSH↓, MMP↓, Cyt‑c↑, Apoptosis↑, P53↑, eff↓, Bcl-xL↓, Bcl-2↓, BAX↑, Casp↑, TumCG↓, TumVol↓, TumW↓,
1563- Api,  MET,    Metformin-induced ROS upregulation as amplified by apigenin causes profound anticancer activity while sparing normal cells
- in-vitro, Nor, HDFa - in-vitro, PC, AsPC-1 - in-vitro, PC, MIA PaCa-2 - in-vitro, Pca, DU145 - in-vitro, Pca, LNCaP - in-vivo, NA, NA
selectivity↑, selectivity↑, selectivity↓, ROS↑, eff↑, tumCV↓, MMP↓, Dose∅, eff↓, DNAdam↑, Apoptosis↑, TumAuto↑, Necroptosis↑, p‑P53↑, BIM↑, BAX↑, p‑PARP↑, Casp3↑, Casp8↑, Casp9↑, Cyt‑c↑, Bcl-2↓, AIF↑, p62↑, LC3B↑, MLKL↑, p‑MLKL↓, RIP3↑, p‑RIP3↑, TumCG↑, TumW↓,
416- Api,    In Vitro and In Vivo Anti-tumoral Effects of the Flavonoid Apigenin in Malignant Mesothelioma
- vitro+vivo, NA, NA
Bax:Bcl2↑, P53↑, ROS↑, Casp9↑, Casp8↑, cl‑PARP1↑, p‑ERK⇅, p‑JNK↓, p‑p38↑, p‑Akt↓, cJun↓, NF-kB↓, EGFR↓, TumCCA↑,
556- ART/DHA,    Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing
- Review, NA, NA
IL6↓, IL1↓, TNF-α↓, TGF-β↓, NF-kB↓, MIP2↓, PGE2↓, NO↓, Hif1a↓, KDR/FLK-1↓, VEGF↓, MMP2↓, TIMP2↑, ITGB1↑, NCAM↑, p‑ATM↑, p‑ATR↑, p‑CHK1↑, p‑Chk2↑, Wnt/(β-catenin)↓, PI3K↓, Akt↓, ERK↓, cMyc↓, mTOR↓, survivin↓, cMET↓, EGFR↓, cycD1/CCND1↓, cycE1↓, CDK4/6↓, p16↑, p27↑, Apoptosis↑, TumAuto↑, Ferroptosis↑, oncosis↑, TumCCA↑, ROS↑, DNAdam↑, RAD51↓, HR↓,
558- ART/DHA,    Artemisinin and Its Synthetic Derivatives as a Possible Therapy for Cancer
- Review, NA, NA
ROS↑, oncosis↑, Apoptosis↑, LysoPr↑, TumAuto↑, Wnt/(β-catenin)↑, AMP↓, NF-kB↓, Myc↓, CREBBP↓, mTOR↓, E-cadherin↑,
559- ART/DHA,    Artemisinin and its derivatives: a promising cancer therapy
- Review, NA, NA
ROS↑,
1076- ART/DHA,    The Potential Mechanisms by which Artemisinin and Its Derivatives Induce Ferroptosis in the Treatment of Cancer
- Review, NA, NA
Ferroptosis↑, ROS↑, ER Stress↑, i-Iron↓, TumAuto↑, AMPK↑, mTOR↑, P70S6K↑, Fenton↑, lipid-P↑, ROS↑, ChemoSen↑, NRF2↑, NRF2↓,
3176- Ash,    Apoptosis is induced in leishmanial cells by a novel protein kinase inhibitor withaferin A and is facilitated by apoptotic topoisomerase I-DNA complex
- in-vitro, NA, NA
PKCδ↓, TOP1∅, ROS↑, GSH↓, DNAdam↑, MMP↓, Cyt‑c↑,
1360- Ash,  immuno,    Withaferin A Increases the Effectiveness of Immune Checkpoint Blocker for the Treatment of Non-Small Cell Lung Cancer
- in-vitro, Lung, H1650 - in-vitro, Lung, A549 - in-vitro, CRC, HCT116 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
PD-L1↑, eff↓, ROS↑, ER Stress↑, Apoptosis↑, BAX↑, Bak↑, BAD↑, Bcl-2↓, XIAP↓, survivin↓, cl‑PARP↑, CHOP↑, p‑eIF2α↑, ICD↑, eff↑,
1363- Ash,  doxoR,    Withaferin A Synergizes the Therapeutic Effect of Doxorubicin through ROS-Mediated Autophagy in Ovarian Cancer
- in-vitro, Ovarian, A2780S - in-vitro, Ovarian, CaOV3 - in-vivo, NA, NA
ChemoSen↑, ROS↑, DNAdam↑, TumCCA↑, LC3B↑, TumCG↓, cl‑Casp3↑,
874- B-Gluc,    Potential promising anticancer applications of β-glucans: a review
- Review, NA, NA
AntiCan↑, TumCG↓, BAX↑, Bcl-2↓, IFN-γ↑, PI3K/Akt↑, MAPK↑, NFAT↑, NF-kB↑, ROS↑, NK cell↑, TumCCA↑, ERK↓, Telomerase↓,
1532- Ba,    Baicalein as Promising Anticancer Agent: A Comprehensive Analysis on Molecular Mechanisms and Therapeutic Perspectives
- Review, NA, NA
ROS↑, ER Stress↑, Ca+2↑, MMPs↓, Cyt‑c↑, Casp3↑, ROS↑, DR5↑, ROS↑, BAX↑, Bcl-2↓, MMP↓, Casp3↑, Casp9↑, P53↑, p16↑, P21↑, p27↑, HDAC10↑, MDM2↓, Apoptosis↑, PI3K↓, Akt↓, p‑Akt↓, p‑mTOR↓, NF-kB↓, p‑IκB↓, IκB↑, BAX↑, Bcl-2↓, ROS⇅, BNIP3↑, p38↑, 12LOX↓, Mcl-1↓, Wnt?, GLI2↓, AR↓, eff↑,
2021- BBR,    Berberine: An Important Emphasis on Its Anticancer Effects through Modulation of Various Cell Signaling Pathways
- Review, NA, NA
*antiOx?, *Inflam↓, Apoptosis↑, TumCCA↑, BAX↑, eff↑, VEGF↓, PI3K↓, Akt↓, mTOR↓, Telomerase↓, β-catenin/ZEB1↓, Wnt↓, EGFR↓, AP-1↓, NF-kB↓, COX2↑, NRF2↓, RadioS↑, STAT3↓, ERK↓, AR↓, ROS↑, eff↑, selectivity↑, selectivity↑, BioAv↓, DNMT1↓, cMyc↓,
1299- BBR,    Effects of Berberine and Its Derivatives on Cancer: A Systems Pharmacology Review
- Review, NA, NA
TumCCA↑, TP53↑, COX2↓, Bax:Bcl2↑, ROS↑, VEGFR2↓, Akt↓, ERK↓, MMP2↓, MMP9↓, IL8↑, P21↑, p27↑, E-cadherin↓, Fibronectin↓, cMyc↓,
1375- BBR,    13-[CH2CO-Cys-(Bzl)-OBzl]-Berberine: Exploring The Correlation Of Anti-Tumor Efficacy With ROS And Apoptosis Protein
- in-vitro, CRC, HCT8 - in-vivo, NA, NA
ROS↑, TumCP↓, XIAP↓, TumCG↓, *toxicity↓,
1399- BBR,  Rad,    Radiotherapy Enhancing and Radioprotective Properties of Berberine: A Systematic Review
- Review, NA, NA
*ROS↓, *MDA↓, *TNF-α↓, *TGF-β↓, *IL10↑, ROS↑, DNAdam↑, mtDam↑, MMP↓, Apoptosis↑, TumCCA↑, Hif1a↓, VEGF↓, RadioS↑,
5583- BetA,    Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells
- vitro+vivo, NA, NA
ROS↑, Bcl-2↓, BAX↑, TOP1↝, eff↝, toxicity↓, toxicity↓, selectivity↑,
2733- BetA,    Betulinic Acid Inhibits Cell Proliferation in Human Oral Squamous Cell Carcinoma via Modulating ROS-Regulated p53 Signaling
- in-vitro, Oral, KB - in-vivo, NA, NA
TumCP↓, TumVol↓, mt-Apoptosis↑, Casp3↑, Casp9↑, BAX↑, Bcl-2↑, OCR↓, TumCCA↑, ROS↑, eff↓, P53↑, STAT3↓, cycD1/CCND1↑,
2738- BetA,    Betulinic Acid Suppresses Breast Cancer Metastasis by Targeting GRP78-Mediated Glycolysis and ER Stress Apoptotic Pathway
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, BT549 - in-vivo, NA, NA
TumCI↓, TumCMig↓, Glycolysis↓, lactateProd↓, GRP78/BiP↑, ER Stress↑, PERK↑, p‑eIF2α↑, β-catenin/ZEB1↓, cMyc↓, ROS↑, angioG↓, Sp1/3/4↓, DNAdam↑, TOP1↓, TumMeta↓, MMP2↓, MMP9↓, N-cadherin↓, Vim↓, E-cadherin↑, EMT↓, LDHA↓, p‑PDK1↓, PDK1↓, ECAR↓, OCR↓, Hif1a↓, STAT3↓,
2745- BetA,    Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and -independent downregulation of specificity proteins (Sp) transcription factors
- in-vitro, CRC, RKO - in-vitro, CRC, SW480 - in-vivo, NA, NA
Apoptosis↑, TumCG↓, Sp1/3/4↓, survivin↓, VEGF↓, p65↓, EGFR↓, cycD1/CCND1↓, ROS↑, MMP↓,
746- Bor,    Organoboronic acids/esters as effective drug and prodrug candidates in cancer treatments: challenge and hope
- Review, NA, NA
eff↑, *toxicity↓, ROS↑, LAT↓, AntiCan↑, AR↓, PSMB5↓, IGF-1↓, PSA↓, TumVol↓, eff↑, Rho↓, Cdc42↓, Ca+2↓, eff↑,
726- Bor,    Redox Mechanisms Underlying the Cytostatic Effects of Boric Acid on Cancer Cells—An Issue Still Open
- Review, NA, NA
NAD↝, SAM-e↝, PSA↓, IGF-1↓, Cyc↓, P21↓, p‑MEK↓, p‑ERK↓, ROS↑, SOD↓, Catalase↓, MDA↑, GSH↓, IL1↓, IL6↓, TNF-α↓, BRAF↝, MAPK↝, PTEN↝, PI3K/Akt↝, eIF2α↑, ATF4↑, ATF6↑, NRF2↑, BAX↑, BID↑, Casp3↑, Casp9↑, Bcl-2↓, Bcl-xL↓,
2047- Buty,    Sodium butyrate inhibits migration and induces AMPK-mTOR pathway-dependent autophagy and ROS-mediated apoptosis via the miR-139-5p/Bmi-1 axis in human bladder cancer cells
- in-vitro, CRC, T24/HTB-9 - in-vitro, Nor, SV-HUC-1 - in-vitro, Bladder, 5637 - in-vivo, NA, NA
HDAC↓, AntiTum↑, TumCMig↓, AMPK↑, mTOR↑, TumAuto↑, ROS↑, miR-139-5p↑, BMI1↓, TumCI?, E-cadherin↑, N-cadherin↓, Vim↓, Snail↓, cl‑PARP↑, cl‑Casp3↑, BAX↑, Bcl-2↓, Bcl-xL↓, MMP↓, PINK1↑, PARK2↑, TumMeta↓, TumCG↓, LC3II↑, p62↓, eff↓,
5910- CAR,    Oregano Phytocomplex Induces Programmed Cell Death in Melanoma Lines via Mitochondria and DNA Damage
- in-vitro, Melanoma, B16-F10 - NA, NA, A375
ROS↑, TumCP↓, Apoptosis↑, Necroptosis↑, mtDam↑, DNAdam↑, selectivity↑, Dose↝, MPT↓,

Showing Research Papers: 1 to 50 of 174
Page 1 of 4 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 174

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

Catalase↓, 3,   Fenton↑, 1,   Ferroptosis↓, 1,   Ferroptosis↑, 2,   frataxin↑, 1,   GPx↑, 1,   GSH↓, 8,   GSH/GSSG↓, 1,   HO-1↓, 1,   ICD↑, 1,   i-Iron↓, 1,   lipid-P↑, 1,   MDA↑, 2,   NADPH/NADP+↓, 1,   NRF2↓, 3,   NRF2↑, 4,   OXPHOS↓, 1,   PARK2↑, 1,   RNS↓, 1,   ROS↑, 51,   ROS⇅, 1,   SAM-e↝, 1,   SIRT3↓, 1,   SOD↓, 2,   xCT↑, 1,  

Mitochondria & Bioenergetics

AIF↑, 1,   ATP↓, 1,   p‑MEK↓, 1,   MMP↓, 9,   MPT↓, 1,   mtDam↑, 6,   OCR↓, 2,   PINK1↑, 1,   XIAP↓, 3,  

Core Metabolism/Glycolysis

12LOX↓, 1,   AMP↓, 1,   AMPK↑, 2,   cMyc↓, 4,   ECAR↓, 1,   GlucoseCon↓, 1,   Glycolysis↓, 2,   HK2↓, 1,   lactateProd↓, 1,   LAT↓, 1,   LDHA↓, 1,   LDL↓, 1,   NAD↝, 1,   NADPH↓, 1,   PDK1↓, 1,   p‑PDK1↓, 1,   PI3K/Akt↑, 1,   PI3K/Akt↝, 1,   PSMB5↓, 1,  

Cell Death

Akt↓, 6,   p‑Akt↓, 3,   Apoptosis↑, 17,   mt-Apoptosis↑, 1,   BAD↑, 1,   Bak↑, 1,   BAX↑, 14,   Bax:Bcl2↑, 3,   Bcl-2↓, 12,   Bcl-2↑, 1,   Bcl-xL↓, 4,   BID↑, 1,   BIM↑, 1,   Casp↑, 1,   Casp3↑, 7,   cl‑Casp3↑, 2,   Casp8↑, 2,   Casp9↑, 6,   p‑Chk2↑, 1,   CK2↓, 1,   Cyt‑c↑, 7,   DR5↑, 1,   Ferroptosis↓, 1,   Ferroptosis↑, 2,   JNK↑, 1,   p‑JNK↓, 1,   MAPK↑, 1,   MAPK↝, 1,   Mcl-1↓, 2,   MDM2↓, 2,   MLKL↑, 1,   p‑MLKL↓, 1,   Myc↓, 1,   Necroptosis↑, 2,   oncosis↑, 2,   p27↑, 3,   p38↑, 2,   p‑p38↑, 1,   survivin↓, 5,   Telomerase↓, 3,  

Kinase & Signal Transduction

AMPKα↑, 1,   Sp1/3/4↓, 2,  

Transcription & Epigenetics

cJun↓, 1,   tumCV↓, 1,  

Protein Folding & ER Stress

ATF6↑, 1,   CHOP↑, 1,   eIF2α↑, 1,   p‑eIF2α↑, 2,   ER Stress↑, 8,   GRP78/BiP↑, 1,   HSP90↓, 1,   PERK↑, 1,   UPR↑, 1,  

Autophagy & Lysosomes

p‑Beclin-1↑, 1,   BNIP3↑, 1,   LC3B↑, 2,   LC3II↑, 1,   p62↓, 1,   p62↑, 1,   TumAuto↑, 6,  

DNA Damage & Repair

p‑ATM↑, 1,   p‑ATR↑, 1,   p‑CHK1↑, 1,   DNAdam↑, 11,   DNMT1↓, 1,   HR↓, 1,   MGMT↓, 1,   p16↑, 2,   P53↑, 6,   p‑P53↑, 1,   p‑PARP↑, 1,   cl‑PARP↑, 2,   cl‑PARP1↑, 1,   RAD51↓, 1,   SIRT6↓, 1,   TP53↑, 1,  

Cell Cycle & Senescence

Cyc↓, 1,   cycD1/CCND1↓, 2,   cycD1/CCND1↑, 1,   cycE1↓, 1,   P21↓, 1,   P21↑, 3,   TumCCA↑, 10,  

Proliferation, Differentiation & Cell State

BMI1↓, 1,   BRAF↝, 1,   cMET↓, 1,   CREBBP↓, 1,   CSCs↓, 1,   EMT↓, 4,   ERK↓, 4,   p‑ERK↓, 2,   p‑ERK⇅, 1,   FOXM1↓, 1,   FOXO3↑, 2,   GSK‐3β↓, 1,   p‑GSK‐3β↓, 1,   HDAC↓, 2,   HDAC10↑, 1,   IGF-1↓, 2,   mTOR↓, 3,   mTOR↑, 2,   p‑mTOR↓, 1,   Nanog↓, 1,   OCT4↓, 1,   P70S6K↑, 1,   PI3K↓, 4,   PTEN↝, 1,   STAT3↓, 3,   p‑STAT3↓, 1,   TOP1↓, 1,   TOP1↝, 1,   TOP1∅, 1,   TumCG↓, 10,   TumCG↑, 1,   Wnt?, 1,   Wnt↓, 1,   Wnt/(β-catenin)↓, 1,   Wnt/(β-catenin)↑, 1,  

Migration

AP-1↓, 1,   Ca+2↓, 1,   Ca+2↑, 1,   Cdc42↓, 1,   CDK4/6↓, 1,   E-cadherin↓, 1,   E-cadherin↑, 3,   FAK↓, 2,   Fibronectin↓, 1,   GLI2↓, 1,   ITGB1↓, 1,   ITGB1↑, 1,   ITGB3↓, 1,   LysoPr↑, 1,   miR-139-5p↑, 1,   MMP2↓, 5,   MMP9↓, 4,   MMP9↑, 1,   MMPs↓, 3,   N-cadherin↓, 2,   NCAM↑, 1,   NFAT↑, 1,   PKCδ↓, 1,   Rho↓, 1,   RIP3↑, 1,   p‑RIP3↑, 1,   Snail↓, 2,   TGF-β↓, 1,   TIMP2↑, 1,   TumCI?, 1,   TumCI↓, 1,   TumCMig↓, 2,   TumCP↓, 5,   TumMeta↓, 2,   Vim↓, 3,   Zeb1↓, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature

angioG↓, 3,   ATF4↑, 1,   EGFR↓, 4,   EPR↝, 1,   Hif1a↓, 5,   Hif1a↑, 1,   KDR/FLK-1↓, 1,   NO↓, 1,   VEGF↓, 4,   VEGFR2↓, 1,  

Barriers & Transport

BBB↑, 1,  

Immune & Inflammatory Signaling

COX2↓, 2,   COX2↑, 1,   IFN-γ↑, 1,   IL1↓, 2,   IL1↑, 1,   IL6↓, 2,   IL8↑, 2,   Inflam↓, 1,   IκB↑, 1,   p‑IκB↓, 1,   MIP2↓, 1,   NF-kB↓, 8,   NF-kB↑, 1,   NK cell↑, 1,   p65↓, 2,   PD-L1↑, 1,   PGE2↓, 1,   PSA↓, 2,   TNF-α↓, 2,   TNF-α↑, 1,  

Hormonal & Nuclear Receptors

AR↓, 3,   ERα/ESR1↓, 1,  

Drug Metabolism & Resistance

BioAv↓, 1,   ChemoSen↑, 4,   ChemoSen∅, 1,   Dose↝, 2,   Dose∅, 3,   eff↓, 6,   eff↑, 25,   eff↝, 2,   RadioS↑, 5,   selectivity↓, 1,   selectivity↑, 9,  

Clinical Biomarkers

AR↓, 3,   BP↓, 1,   BRAF↝, 1,   EGFR↓, 4,   ERα/ESR1↓, 1,   FOXM1↓, 1,   GutMicro↝, 1,   IL6↓, 2,   Myc↓, 1,   PD-L1↑, 1,   PSA↓, 2,   TP53↑, 1,  

Functional Outcomes

AntiCan↑, 2,   AntiTum↑, 1,   chemoP↑, 2,   cognitive↑, 1,   memory↑, 1,   neuroP↑, 1,   OS↑, 1,   RenoP↑, 1,   toxicity↓, 3,   TumVol↓, 4,   TumW↓, 3,  

Infection & Microbiome

Bacteria↓, 1,  
Total Targets: 276

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress

antiOx?, 1,   antiOx↑, 3,   GSH↑, 1,   HO-1↑, 1,   lipid-P↓, 1,   MDA↓, 1,   NRF2↑, 2,   ROS↓, 4,   ROS↑, 2,   ROS∅, 1,   SOD1↑, 1,  

Metal & Cofactor Biology

IronCh↑, 1,  

Core Metabolism/Glycolysis

Acetyl-CoA↑, 1,   GlucoseCon↑, 1,  

Transcription & Epigenetics

Ach↑, 1,  

Migration

TGF-β↓, 1,  

Barriers & Transport

BBB↝, 1,  

Immune & Inflammatory Signaling

IL10↑, 1,   Inflam↓, 2,   TNF-α↓, 1,  

Synaptic & Neurotransmission

ChAT↑, 1,  

Drug Metabolism & Resistance

BioAv↓, 1,  

Functional Outcomes

AntiAge↑, 1,   AntiCan↑, 1,   cardioP↑, 1,   cognitive↑, 1,   memory↑, 1,   neuroP↑, 1,   toxicity↓, 6,   Weight↓, 1,  
Total Targets: 30

Scientific Paper Hit Count for: ROS, Reactive Oxygen Species
18 Silver-NanoParticles
14 Vitamin C (Ascorbic Acid)
13 Copper and Cu NanoParticles
13 Magnetic Fields
13 Quercetin
6 EGCG (Epigallocatechin Gallate)
5 Apigenin (mainly Parsley)
5 Berberine
5 Shikonin
4 Alpha-Lipoic-Acid
4 Artemisinin
4 Betulinic acid
4 Curcumin
4 Honokiol
4 Piperlongumine
3 Cisplatin
3 Ashwagandha(Withaferin A)
3 Resveratrol
3 Chemotherapy
3 Graviola
3 Selenium NanoParticles
3 Silymarin (Milk Thistle) silibinin
2 Radiotherapy/Radiation
2 3-bromopyruvate
2 SonoDynamic Therapy UltraSound
2 Zinc
2 doxorubicin
2 immunotherapy
2 Boron
2 Coenzyme Q10
2 diet FMD Fasting Mimicking Diet
2 Aflavin-3,3′-digallate
2 Gambogic Acid
2 Garcinol
2 Juglone
2 Luteolin
2 Melatonin
2 Naringin
2 Parthenolide
2 Thymoquinone
1 2-DeoxyGlucose
1 cetuximab
1 Photodynamic Therapy
1 Allicin (mainly Garlic)
1 Andrographis
1 Metformin
1 beta-glucans
1 Baicalein
1 Butyrate
1 Carvacrol
1 Catechins
1 Vitamin E
1 Black phosphorus
1 chemodynamic therapy
1 Dichloroacetate
1 diet Methionine-Restricted Diet
1 diet Plant based
1 Emodin
1 Paclitaxel
1 γ-linolenic acid (Borage Oil)
1 Gold NanoParticles
1 Hydroxycinnamic-acid
1 Hyperthermia
1 HydroxyTyrosol
1 Methyl Jasmonate
1 Magnetic Field Rotating
1 Methylglyoxal
1 Nimbolide
1 Propyl gallate
1 Piperine
1 Rosmarinic acid
1 Selenium
1 triptolide
1 VitK3,menadione
1 Iron
1 Magnesium
1 Vitamin K2
1 Zinc Oxide
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:0  Cells:%  prod#:%  Target#:275  State#:%  Dir#:2
wNotes=0 sortOrder:rid,rpid

 

Home Page